Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ziga Rotar

Showing results (11-20 of 63) with videos related to

Pageof 7
Sort By:
Medicine|April 9, 2016
Do Early Diagnosis and Glucocorticoid Treatment Decrease the Risk of Permanent Visual Loss and Early Relapses in Giant Cell Arteritis: A Prospective Longitudinal StudyAlojzija Hocevar, Ziga Rotar, Rok Jese, et al.
Acta Reumatologica Portuguesa|October 25, 2006
Roadmap to vasculitisYrjö T Konttinen, Ziga Rotar, Tom Pettersson, et al.
Arthritis Research & Therapy|March 4, 2016
IgA vasculitis in adults: the performance of the EULAR/PRINTO/PRES classification criteria in adultsAlojzija Hočevar, Ziga Rotar, Vesna Jurčić, et al.
RMD Open|November 30, 2018
Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registriesKim Lauper, Denis Mongin, Florenzo Iannone, et al.
Seminars in Arthritis and Rheumatism|July 9, 2019
Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritisKim Lauper, Denis Mongin, Florenzo Iannone, et al.
The Journal of Rheumatology|January 17, 2017
Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA CollaborationKaterina Chatzidionysiou, Elisabeth Lie, Galina Lukina, et al.
RMD Open|November 18, 2021
Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatologyKim Lauper, Joanna Kedra, Maarten de Wit, et al.
Annals of the Rheumatic Diseases|January 21, 2022
EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatologyDelphine Sophie Courvoisier, Kim Lauper, Joanna Kedra, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 6, 2026
Machine Learning to Predict Remission Between Six and 24 Months in Rheumatoid Arthritis: Insights from the JAK-pot CollaborationZubeyir Salis, Denis Mongin, Denis Choquette, et al.
Seminars in Arthritis and Rheumatism|February 21, 2026
Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study): effect of regulatory warningsDenis Mongin, Romain Aymon, Denis Choquette, et al.
Pageof 7

Showing results (11-20 of 63) with videos related to

Sort By:
Pageof 7
Medicine|April 9, 2016
Do Early Diagnosis and Glucocorticoid Treatment Decrease the Risk of Permanent Visual Loss and Early Relapses in Giant Cell Arteritis: A Prospective Longitudinal StudyAlojzija Hocevar, Ziga Rotar, Rok Jese, et al.
Acta Reumatologica Portuguesa|October 25, 2006
Roadmap to vasculitisYrjö T Konttinen, Ziga Rotar, Tom Pettersson, et al.
Arthritis Research & Therapy|March 4, 2016
IgA vasculitis in adults: the performance of the EULAR/PRINTO/PRES classification criteria in adultsAlojzija Hočevar, Ziga Rotar, Vesna Jurčić, et al.
RMD Open|November 30, 2018
Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registriesKim Lauper, Denis Mongin, Florenzo Iannone, et al.
Seminars in Arthritis and Rheumatism|July 9, 2019
Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritisKim Lauper, Denis Mongin, Florenzo Iannone, et al.
The Journal of Rheumatology|January 17, 2017
Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA CollaborationKaterina Chatzidionysiou, Elisabeth Lie, Galina Lukina, et al.
RMD Open|November 18, 2021
Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatologyKim Lauper, Joanna Kedra, Maarten de Wit, et al.
Annals of the Rheumatic Diseases|January 21, 2022
EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatologyDelphine Sophie Courvoisier, Kim Lauper, Joanna Kedra, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 6, 2026
Machine Learning to Predict Remission Between Six and 24 Months in Rheumatoid Arthritis: Insights from the JAK-pot CollaborationZubeyir Salis, Denis Mongin, Denis Choquette, et al.
Seminars in Arthritis and Rheumatism|February 21, 2026
Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study): effect of regulatory warningsDenis Mongin, Romain Aymon, Denis Choquette, et al.
Pageof 7